Pancreatic Cancer Research

ResearcherPeking University Cancer HospitalActive in the last 2 years

Dao-Ning Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3287-5592; OpenAlex author ID A5013171771. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. Close, But no Cigar: Comparative Evaluation of ChatGPT-4o and OpenAI o1-preview in Answering Pancreatic Ductal Adenocarcinoma-Related Questions Co-author DOI 10.1101/2025.07.26.25332239↗
  2. Identification of the γ-glutamyl cycle as a novel therapeutic target and 5-oxoproline as a new biomarker for diagnosing pancreatic cancer. Co-author DOI 10.1080/07853890.2023.2242247↗
  3. Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.13950↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Zhao · 2 shared papers, 2017–2023 · strength 0.26
  2. Chunyi Hao · 2 shared papers, 2017–2023 · strength 0.26
  3. Chengpeng Li · 1 shared paper, 2025 · strength 0.26
  4. Cui Yang · 1 shared paper, 2025 · strength 0.26
  5. Weijia Wang · 1 shared paper, 2023 · strength 0.18
  6. Jianhui Wu · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.